|
1. BIOLOGIE
|
|
|
|
2.6 ETIOLOGIE - ENVIRONNEMENT
|
|
|
|
|
3.1 PRÉVENTION - TABAC
|
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
|
|
|
|
|
3.3 PRÉVENTION - VACCINS
|
|
|
|
3.6 PRÉVENTION - ACTIVITÉ PHYSIQUE
|
|
|
|
4.1 DÉP., DIAG. & PRONO. - PROSTATE
|
|
|
Prostate Cancer Modeling Study Supports Precision Screening Approach [Genome Web]
|
|
|
|
|
|
To explore the potential benefit-harm and cost-effectiveness of various prostate cancer screening strategies, Pashayan and colleagues in the UK modeled the potential deaths prevented, overdiagnoses, direct health care costs, and more in a simulated cohort of nearly 4.5 million 55- to 69-year-old men in England, followed until the age of 90.
|
|
|
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
|
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
|
|
|
|
5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS
|
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
5.12.13 IMMUNOTHÉRAPIES - BIOMARQUEURS
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH
|
|
|
|
5.2 PHARMA
|
|
|
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
|
|
|
|
5.3.4.1 TRAITEMENTS - AMM (FDA, EMA,...) - ENHERTU
|
|
|
|
|
|
|
|
|
5.3.4.2 TRAITEMENTS - AMM (FDA, EMA,...) - LYNPARZA
|
|
|
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
|
6.3 ASSOCIATIONS/FONDATIONS
|
|
|